TOMAS: revisiting PARP inhibitor combination therapy

Lancet Oncol. 2018 Oct;19(10):1269-1270. doi: 10.1016/S1470-2045(18)30494-7. Epub 2018 Sep 11.

Authors

Benjamin A Nacev¹, William D Tap²

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA; The Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY, USA.
² Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: tapw@mkscc.org.

PMID: 30217674
DOI: 10.1016/S1470-2045(18)30494-7

No abstract available

Publication types

Comment

MeSH terms

Humans
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors*
Sarcoma*
Trabectedin

Substances

Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
Trabectedin
olaparib